Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|November 9, 2016
Curcumin: New Use for an Old Spice?
Author(s)James Phelps, MD
Although recent reviews caution against overenthusiasm, what if a simple, inexpensive, and extremely low-risk anti-inflammatory was at hand?
Advertisement
View the information in PDF format.
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Advertisement
Advertisement